WO1990001541A1 - In vitro propagation of embryonic stem cells - Google Patents

In vitro propagation of embryonic stem cells Download PDF

Info

Publication number
WO1990001541A1
WO1990001541A1 PCT/AU1989/000330 AU8900330W WO9001541A1 WO 1990001541 A1 WO1990001541 A1 WO 1990001541A1 AU 8900330 W AU8900330 W AU 8900330W WO 9001541 A1 WO9001541 A1 WO 9001541A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
lif
culture medium
animal
embryos
Prior art date
Application number
PCT/AU1989/000330
Other languages
English (en)
French (fr)
Inventor
Robert Lindsay Williams
Nicholas Martin Gough
Douglas James Hilton
Original Assignee
Amrad Corporation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amrad Corporation Limited filed Critical Amrad Corporation Limited
Priority to EP89909126A priority Critical patent/EP0380646B1/de
Priority to DE68928914T priority patent/DE68928914T2/de
Publication of WO1990001541A1 publication Critical patent/WO1990001541A1/en
Priority to DK199100170A priority patent/DK176238B1/da
Priority to NO19910385A priority patent/NO322243B1/no
Priority to HK98102359A priority patent/HK1003208A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Definitions

  • This invention relates to the use of a previously discovered and characterised molecule, leukaemia
  • LIF inhibitory factor
  • Embryonic stem (ES) cells the pluripotent outgrowths of blastocysts, can be cultured and manipulated in vitro and then returned to the embryonic environment to contribute normally to all tissues including the germline (for review see Robertson, E.J. (1986) Trends inn Genetics 2:9-13). Not only can ES cells propagated in vitro
  • chimaeras including germline chimaeras, but in addition, these cells can be manipulated in vitro without losing their capacity to generate germ-line chimaeras (Robertson, E.J. et.al. (1986) Nature 323:445-447).
  • ES cells thus provide a route for the generation of transgenic animals such as transgenic mice, a route which has a number of important advantages compared with more conventional techniques, such as zygote injection and viral infection (Wagner and Stewart (1986) in Experimental Approaches to Embryonic Development. J. Rossant and
  • characterised ES cells having a novel introduced gene can be efficiently introduced into embryos by blastocyst injection or embryo aggregation and the consequences of the introduced gene on the development of the resulting transgenic chimaeras monitored during pre- or post-natal life.
  • the site in the ES cell genome at which the introduced gene integrates can be manipulated, leaving the way open for gene targeting and gene replacement
  • ES cells and certain EC (embryonal carcinoma) cell lines will only retain the stem cell phenotype in vitro when cultured on a feeder layer of fibroblasts (such as murine STO cells, e.g. Martin, G.R. and Evans, M.J. (1975) Proc. Natl. Acad. Sci. USA
  • fibroblasts such as murine STO cells, e.g. Martin, G.R. and Evans, M.J. (1975) Proc. Natl. Acad. Sci. USA
  • LIF has the capacity to substitute for, or be added to, feeder layers (or conditioned medium) in supporting the maintenance of pluripotential ES cells in vitro.
  • LIF is a protein that has previously been purified, cloned and produced in large quantities in purified recombinant form from both Escherichia coli and yeast cells.
  • LIF has been defined as a factor, the properties of which include:
  • LIF has now been found to have the following properties:
  • a first aspect of the present invention relates to a method for the isolation of
  • embryonic stem (ES) cells from animal embryos in vitro which method comprises deriving ES cells from said embryos in culture medium, said culture medium containing an effective amount of leukaemia inhibitory factor (LIF), for a time and under conditions sufficient for the development of said ES cells.
  • LIF leukaemia inhibitory factor
  • the embryos used may be isolated from animals including, but not limited to, humans and a number of other animal species such as birds (eg. chickens), mice, sheep, pigs, cattle, goats and fish.
  • a second aspect of the present invention contemplates a process for maintaining animal embryonic stem (ES) cells in vitro while retaining their
  • pluripotential phenotype which process comprises
  • the ES cells in accordance with this aspect of the invention include cells from humans, mice, birds (eg. chickens), sheep, pigs, cattle, goats and fish.
  • the LIF used in the culture medium is preferably recombinant LIF produced, by way of example, in accordance with the methods described in International Patent
  • recombinant LIF and in particular recombinant human and murine LIF are effective substitutes for, or additives to, feeder layers or conditioned medium in maintaining ES cells in vitro.
  • recombinant LIF is produced in E. coli and yeast using the methods described in International Patent Application No.
  • PCT/AU88/00093 it is within the scope of the present invention to include recombinant LIF produced in other hosts including mammalian and insect cells and to synthetic LIF.
  • the present invention extends to ES cells derived from animal embryos by passage in a culture medium containing LIF, to such ES cells having additional genetic material inserted therein, and to chimaeric animals such as chimaeric mice or transgenic progeny of said animals generated by known techniques using ES cells which have been maintained in vitro in a LIF-containing culture medium.
  • the invention extends to the generation and maintenance of ES cells from humans, mice, birds (eg.
  • This invention also includes the use of LIF in culture media to modulate the survival and growth of human and other animal species such as cattle germ cells and embryonic cells, for example, for use in in vitro fertilisation and other procedures.
  • Figure 1 is a graphical representation showing the effect on ES cells of different concentrations of LIF.
  • Figure 2 is a pictorial representation showing ES cell morphology in the presence and absence of LIF.
  • Figure 3 is a graphical (A and C) and pictorial (B) representation showing the binding of I25 I-LIF to ES cells (EKcs-1) and EC cells (F9 and PCC3-A).
  • the present invention is directed to a method for the isolation and maintenance of embryonic stem (ES) cells from animal embryos in vitro which method comprises deriving and/or maintaining said ES cells from said embryos in culture medium containing an effective amount of leukaemia inhibitory factor (LIF), for a time and under conditions sufficient for the derivation and/or
  • LIF leukaemia inhibitory factor
  • the animal embryos may be isolated from a number of animal species such as humans, mice, birds (eg. chickens), sheep, pigs, cattle, goats and fish.
  • animal embryos includes reference to "animal blastocysts”.
  • the present invention is exemplified using human LIF with murine ES cells (heterologous system) and murine LIF with murine ES cells (homologous system). This is done with the understanding that the present invention contemplates LIF from any animal species in heterologous or homologous systems with animal embryos from animal species such as humans, mice, birds (e.g. chickens), sheep, pigs, cattle, goats and fish.
  • heterologous system Although in certain circumstances, a heterologous system will work effectively, it may be preferable to use homologous systems. Given the teachings herein, it will be routine for the skilled technician to ascertain whether a homologous or heterologous system is required in order to isolate or maintain particular animal ES cells.
  • culture medium is meant a suitable medium capable of supporting growth of ES cells.
  • suitable culture media useful in practicing the present invention are Eagles medium or modifications or
  • the culture medium may or may not contain feeder cells and LIF may be used to substitute for, or add to, said feeder cells.
  • LIF or more particularly synthetic or recombinant LIF
  • LIF is added to the medium at a concentration of about 100 - 1,000,000 units/ml and preferably about 100 - 100,000 units/ml and even more preferably 500 - 10,000 units/ml where 50 units are defined as the amount of LIF which in one millilitre induces a 50% reduction in clone formation by murine M1 myeloid cells.
  • recombinant LIF is meant the LIF prepared by genetic engineering means such as, for
  • the effective derivation time is from 1 day to 20 weeks and particularly from 1 to 8 weeks.
  • Another aspect, of the present invention contemplates a process for maintaining animal ES cells in vitro while retaining their pluripotential phenotype which process comprises culturing said cells in a culture medium containing an effective amount of LIF under conditions sufficient to maintain said cells.
  • the ES cells in accordance with this aspect of the invention include cells derived from humans, mice, birds (eg. chickens), sheep, pigs, cattle, goats and fish. As with the isolation of ES cells from animal embryos, the LIF used in the
  • the aformentioned process is preferably recombinant LIF.
  • the culture medium may or may not contain feeder cells.
  • pluripotential cells and “embryonic stem cells” are those which retain the developmental potential to
  • recombinant LIF to maintain the stem cell phenotype of ES cells is demonstrated by transferring ES cells D3 and HD5 into normal cell culture medium in the presence of varying concentrations of purified yeast-derived recombinant human LIF (rY-HLIF) or E. coli - derived recombinant mouse LIF (rE-MLIF).
  • rY-HLIF yeast-derived recombinant human LIF
  • rE-MLIF E. coli - derived recombinant mouse LIF
  • concentrations of 1000 - 5000 units/ml of rY-HLIF or rE-MLIF more than 90% of the D3 and HD5 ES cells retained their stem cell phenotype.
  • the ES cells maintained in normal culture medium differentiated over a period of 3 - 6 days.
  • the proportion of colonies having the stem cell phenotype was related to the concentration of LIF in the culture medium.
  • six new ES cell lines (MBL-1,2,3,4,5 & 6) were isolated from blastocysts in the absence of feeder cells when the media was supplemented with 1000 units/ml rE-HLIF.
  • Long term maintenance of the ES cell lines D3, HD5 and MBL-1 to 6 in LIF for up to 22 passages (approximately 100 cell generations or 10 weeks) did not noticeably alter the growth characteristics of these ES cells or their dose dependency on LIF.
  • the ability of these ES cells to differentiate into all somatic and germ cell linages was confirmed by
  • the present invention also relates to chimaeric animals generated by known techniques using the ES cells contemplated herein. These ES cells may be isolated from animal embryos and/or maintained in vitro according to the subject invention.
  • genetically manipulated ES cells may be passaged in LIF and used to make chimaeric animals.
  • genetically manipulated ES cells containing a retrovirus vector (N-TK527; derived from pXT1; C.A. Boulter and E.F. Wagner, (1987) Nucl. Acids Res. 15:7194) encoding genes for neomycin resistance and c-src 527 were propogated in the presence of LIF but in the absence of feeder cells for over 20 passages. These cells still retained the ability to differentiate as judged by the formation of normal chimaeras following introduction of these cells into preimplantation embryos by blastocyst injection.
  • N-TK527 retrovirus vector
  • This example sets out the steps used to maintain ES cells in vitro in LIF, and to generate chimaeric mice using ES cells so passaged.
  • Step 1 Propagation in vitro:
  • the ES cells used were the D3 (Doetschman, T.C. et.al. (1985) J. Embryo1.Exp.Morphol. 87:27-45) the EKcs-1 (previously known as CS1) (Wagner, E.F. et.al. (1985) Cold Spring Harbor Symp.Quant.Biol. 50:691-700) and the HD5 (C. Stewart, unpublished) ES cell lines isolated from 129 SV He blastocysts and the CBL63 (R.Kemler, unpublished) ES cells isolated from C57BL/6J blastocysts.
  • the D3 and CBL63 cells Prior to culture in LIF, the D3 and CBL63 cells were maintained in Dulbecco modified Eagles medium with 15% (v/v) foetal calf serum on a feeder layer of primary embryo fibroblasts, and the EKcs-1 and HD5 ES cells were maintained in Eagle's medium with 15% (v/v) foetal calf serumand 0.1 mM
  • ⁇ -mecraptoethanol in the presence of medium conditioned by the bladder carcinoma cell line 5637 (ATCC NO.HTB9).
  • fibroblasts for 10 passages were transferred to media containing 1,000-5,000 units ml -1 H-LIF and after a further 7 or 15 passages the cells were transferred into media containing 0-5,000 units ml -1 of H-LIF ( ⁇ - ⁇ ) or 0-1,000 units ml -1 M-LIF ( ⁇ - ⁇ ) respectively.
  • Figure 2 shows ES cell morphology in the presence of recombinant LIF.
  • HD5 ES cells cultured in the presence of 80% 5637 conditioned medium were assayed for the ability of purified recombinant LIF to maintain the stem-cell phenotype by transfer to media containing 1,000 units ml -1 M-LIF (A), or to normal culture media (B).
  • D3 cells maintained in H-LIF for 15 passages were assayed for the ability to differentiate by transfer into media containing 1,000 units ml -1 M-LIF (C) or normal culture media (D).
  • Immunofluorescence of the cells in the two D3 colony types was carried out using the ECMA-7 monoclonal antibody which recognizes a stem cell-specific cell-surface antigen. Cell-surface-specific immunofluorescence was detected on over 90% of the cells maintained in media containing 1,000 units ml -1
  • Figures 1 and 2 indicate that over 90% of the ES cells maintained in 1000-5000 units/ml rY-HLIF or rE-MLIF retained their stem cell phenotype. In contrast, ES cells maintained in normal culture medium differentiated over a period of 3-6 days. The different concentrations of rY-HLIF or rE-MLIF used did not result in any noticeable change in cell number after 6 days in culture, indicating that there is no selection for a specific subpopulation able to grow in LIF. Similar results have been obtained using yeast-derived rMLIF also disclosed in International Patent Application No. PCT/AU88/00093. The data in Figure I indicate that human LIF acts on mouse ES cells, as previously described for the action of human LIF on M1 myeloid leukaemic cells (Gough,N.M. et.al. (1988)
  • Step 2 Isolation of ES cell lines:
  • the blastocysts were allowed to attach to the culture dish and approximately 7 days later the outgrowing inner cell mass picked, trypsinised and transfered to another culture dish in the same culture media.
  • ES cell colonies appeared 2 - 3 weeks later with between 5 - 7 individual colonies arising from each explanted inner cell mass.
  • the ES cell lines were then expanded for further analysis.
  • the second method for isolation of ES cell lines used the immunosurgery
  • D3 ES cells maintained in LIF for 7-22 passages and MBL-1 ES cells maintained in LIF for 14-17 passages were reintroduced into the embryonic environment by blastocyst injection (as described in
  • Blastocysts were isolated from the outbred ICR mouse strain or inbred C57BL/6J mice. The expanded blastocysts were maintained in oil-drop cultures at 4°C for 10 min prior to culture. The ES cells were prepared by picking individual colonies, which were then incubated in phosphate-buffered saline, 0.5 mM EGTA for 5 min; a single cell suspension was prepared by incubation in a trypsin-EDTA solution
  • Chimaeric mice were identified by coat markers (Hogan et al., (1986) Manipulating the Mouse
  • the male chimaeras were tested for germline transmission of ES derived cells by mating to ICR or
  • D3 ES cells were infected with a retrovirus vector (N-TK527) expressing the neomycin resistance gene and a c-src gene mutant (c-src 527 ) (protocol for infection is described in Williams et al., (1988) Cell 52: 121-131).
  • N-TK527 retrovirus vector expressing the neomycin resistance gene and a c-src gene mutant (c-src 527 ) (protocol for infection is described in Williams et al., (1988) Cell 52: 121-131).
  • the ES cell clones isolated were maintained in culture medium
  • D3 and MB1-1 ES cells are derived from 129 Sv He mice (inbred, agouti, homozygous for the glucose phosphate isomerase 1 a allele).
  • the D3 ES cells were originally cultured on primary embryo fibroblasts for 10 passages and then transferred to 1,000-5,000 units/ml recombinant LIF for 7-22 passages.
  • the MB1-1 ES cells were isolated in the absence of feeder cells but in the presence of rE-HLIF these cells were cultured for 14-17 passages. The ES cells were then injected into ICR (outbred, albino) or C57BL/6J (inbred, black) blastocysts which were then transfered into pseudo-pregnant foster mothers.
  • Tissues analysed C, coat; Bl, blood; Sp, spleen; P, pancrease; Li, liver; T, thymus; H, heart; Lu, lungs; G, gonads; K, kidneys; M, muscle; B, brain; Sa, salivary gland.
  • Male chimaeras were mated to ICR or C57BL/6J mice and offspring identified by coat pigmentation.
  • This example sets out the steps used to document specific high affinity receptors on ES and EC cells.
  • results in (A) were standardized to 5 x 10 6 cells per point and the mean of duplicate points are shown and curves were fitted using the Ligand program.
  • B Autoradiography of F9 EC cells labelled with 125 I-labelled LIF.
  • C Quantitation of silver grains on F9 EC cells after binding of 125 I-labelled LIF.
  • Figure 3 illustrates the specific saturable and high affinity binding of 125 I-LIF to the ES cells EKcs-1 and the EC cells PCC3-A and F9.
  • leukaemia which displays 50-200 LIF receptors/cell with an apparent dissociation constant of 50-150 pM. All other ES and EC cells tested - D3 , NG2 , PC13 and P19 - bound similar levels of LIF (data not shown).
  • I-LIF insulin
  • IGF-I insulin
  • IGF-II acidic and basic FGF
  • TGF ⁇ TNF ⁇
  • TNF ⁇ TNF ⁇
  • NGF NGF
  • PDGF EGF
  • IL-1 IL-4
  • G-CSF G-CSF
  • Multi-CSF Multi-CSF

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/AU1989/000330 1988-08-04 1989-08-03 In vitro propagation of embryonic stem cells WO1990001541A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP89909126A EP0380646B1 (de) 1988-08-04 1989-08-03 (in vitro)-vermehrung von embryonalen stammzellen unter verwendung von leukämie-inhibitionsfaktor (lif)
DE68928914T DE68928914T2 (de) 1988-08-04 1989-08-03 (in vitro)-vermehrung von embryonalen stammzellen unter verwendung von leukämie-inhibitionsfaktor (lif)
DK199100170A DK176238B1 (da) 1988-08-04 1991-01-31 In vitro isolering og opretholdelse af embryone stængelceller, (ES)-celler, samt fremgangsmåde til fremstilling af et non-humant kimært dyr
NO19910385A NO322243B1 (no) 1988-08-04 1991-02-01 Fremgangsmater for isolering henholdsvis opprettholdelse av embryoniske stam (ES) celler, fremgangsmate for fremstilling av et kimaerisk dyr, og kimaeriske dyr eller transgenisk avkom derav.
HK98102359A HK1003208A1 (en) 1988-08-04 1998-03-20 Use of leukaemia inhibitory factor (lif) for the (in vitro) propagation of embryonic stem cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPI9644 1988-08-04
AUPI964488 1988-08-04

Publications (1)

Publication Number Publication Date
WO1990001541A1 true WO1990001541A1 (en) 1990-02-22

Family

ID=3773256

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1989/000330 WO1990001541A1 (en) 1988-08-04 1989-08-03 In vitro propagation of embryonic stem cells

Country Status (11)

Country Link
US (1) US5166065A (de)
EP (1) EP0380646B1 (de)
JP (1) JP2740320B2 (de)
AT (1) ATE175994T1 (de)
AU (1) AU623922B2 (de)
CA (1) CA1341469C (de)
DE (1) DE68928914T2 (de)
DK (1) DK176238B1 (de)
HK (1) HK1003208A1 (de)
NO (1) NO322243B1 (de)
WO (1) WO1990001541A1 (de)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0651787A4 (de) * 1990-07-09 1993-07-27 Amrad Corp Ltd Verbesserte implantation, entwicklung und versorgung von embryonen bei verwendung von leukämieinhibtions-faktor.
WO1994024274A1 (en) * 1993-04-21 1994-10-27 The University Of Edinburgh Isolation, selection and propagation of animal transgenic stem cells
WO1994026884A1 (en) * 1993-05-14 1994-11-24 Biotechnology Research And Development Corporation Embryonic stem cells for making chimeric and transgenic ungulates
WO1995006716A1 (en) * 1993-08-30 1995-03-09 Northwestern University Rat pluripotent embryonic stem cells and method of obtaining and using same
WO1995020042A1 (en) * 1994-01-25 1995-07-27 Ppl Therapeutics (Scotland) Limited Embryonic stem cell isolation
FR2726003A1 (fr) * 1994-10-21 1996-04-26 Agronomique Inst Nat Rech Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires
EP0725817A1 (de) * 1993-11-03 1996-08-14 Diacrin, Inc. Stammzellen aus embryonen, die in der lage sind, zu gewünschten zelllinien auszudifferenzieren
WO1997041209A1 (en) * 1996-04-29 1997-11-06 Leuven Research & Development Vzw Pluripotent rabbit embryonic stem (es) cell lines and their use in the generation of chimeric rabbits
US5698763A (en) * 1991-11-14 1997-12-16 Weissmann; Charles Transgenic animals lacking prion proteins
WO1997047734A1 (en) * 1996-06-14 1997-12-18 The Regents Of The University Of California In vitro derivation and culture of primate pluripotent stem cells and therapeutic uses thereof
WO1998039416A1 (en) * 1997-03-06 1998-09-11 Infigen, Inc. Method of cloning animals
US6395958B1 (en) 1997-03-06 2002-05-28 Infigen, Inc. Method of producing a polypeptide in an ungulate
WO2003054170A1 (en) * 2001-12-21 2003-07-03 Thromb-X Nv Compositions for the in vitro derivation and culture of embryonic stem (es) cell lines with germline transmission capability and for the culture of adult stem cells
WO2003054169A1 (en) * 2001-12-21 2003-07-03 Thromb-X Nv Compositions for the in vitro derivation and culture of embryonic stem (es) cell lines with germline transmission capability
WO2004039965A1 (ja) * 2002-10-31 2004-05-13 Riken 多能性幹細胞培養用の組成物とその使用
US7145057B2 (en) 2002-02-01 2006-12-05 Origen Therapeutics, Inc. Chimeric bird from embryonic stem cells
US8962311B2 (en) 2006-08-09 2015-02-24 Valneva Method of obtaining chicken embryonic stem cells
US9260694B2 (en) 2007-04-24 2016-02-16 Valneva Generation of duck cell lines
US9382513B2 (en) 2002-03-08 2016-07-05 Valneva Method of making an avian cell line

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032178A1 (en) * 1988-08-04 2003-02-13 Williams Robert Lindsay In vitro propagation of embryonic stem cells
EP0453453B1 (de) * 1989-01-10 1996-09-11 Amrad Corporation Limited Leukämiehemmender faktor aus vieharten und seine verwendung zur verbesserung der implantation und der entwicklung von embryonalen zellen
AU622515B2 (en) * 1989-01-10 1992-04-09 Amrad Operations Pty. Limited Leukaemia inhibitory factor from livestock species and use thereof to enhance implantation and development of embryonic cells
US5705732A (en) * 1989-06-12 1998-01-06 Oklahoma Medical Research Foundation Universal donor cells
JP3040815B2 (ja) * 1989-11-24 2000-05-15 モナッシュ・ユニバーシティ 随伴細胞に及ぼす白血病抑制因子の増殖作用
DE69119759T2 (de) * 1990-03-20 1997-01-16 Amrad Corp Ltd Verfahren zur steuerung der neuronentwicklung und des neuronunterhalts
US7153684B1 (en) * 1992-10-08 2006-12-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5690926A (en) * 1992-10-08 1997-11-25 Vanderbilt University Pluripotential embryonic cells and methods of making same
US5453357A (en) * 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
DE69434934D1 (de) * 1993-10-14 2007-04-12 Harvard College Verfahren zur induzierung und zur erhaltung neuronalen zellen
US6686198B1 (en) 1993-10-14 2004-02-03 President And Fellows Of Harvard College Method of inducing and maintaining neuronal cells
US5874301A (en) * 1994-11-21 1999-02-23 National Jewish Center For Immunology And Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5728581A (en) * 1995-06-07 1998-03-17 Systemix, Inc. Method of expanding hematopoietic stem cells, reagents and bioreactors for use therein
EP0882127A4 (de) 1996-01-09 2002-09-11 Univ California Embryonische stammzellen-ähnliche zellen von huftieren, verfahren zur herstellung und verwendung der zellen zur herstellung transgener huftiere
WO1997025413A1 (en) 1996-01-09 1997-07-17 The Regents Of The University Of California Ungulate embryonic stem-like cells, making and using the cells to produce a transgenic ungulate
US6247995B1 (en) 1996-02-06 2001-06-19 Bruce Bryan Bioluminescent novelty items
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
EP0885308A4 (de) * 1996-02-28 2002-02-27 Univ Vanderbilt Verbindungen und methoden zur herstellung embryonaler stammzellen
US7544511B2 (en) * 1996-09-25 2009-06-09 Neuralstem Biopharmaceuticals Ltd. Stable neural stem cell line methods
US6416960B1 (en) 1996-08-08 2002-07-09 Prolume, Ltd. Detection and visualization of neoplastic tissues and other tissues
US6458547B1 (en) 1996-12-12 2002-10-01 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
US6090622A (en) * 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
US6331406B1 (en) 1997-03-31 2001-12-18 The John Hopkins University School Of Medicine Human enbryonic germ cell and methods of use
AU729377B2 (en) 1997-10-23 2001-02-01 Asterias Biotherapeutics, Inc. Methods and materials for the growth of primate-derived primordial stem cells in feeder-free culture
US6027937A (en) * 1998-08-18 2000-02-22 Harper; William Method for propagation of insecta germ cells
US6767737B1 (en) * 1998-08-31 2004-07-27 New York University Stem cells bearing an FGF receptor on the cell surface
US20020168766A1 (en) * 2000-01-11 2002-11-14 Gold Joseph D. Genetically altered human pluripotent stem cells
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
US7410798B2 (en) * 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
NZ516738A (en) * 1999-07-20 2004-01-30 Univ Southern California Identification of pluripotent pre-mesenchymal, pre-hematopoietic progenitor cells expressing a unique molecular marker
US6333192B1 (en) 1999-08-09 2001-12-25 North Carolina State University Method of producing an undifferentiated avian cell culture using avian primordial germ cells
US7455983B2 (en) * 2000-01-11 2008-11-25 Geron Corporation Medium for growing human embryonic stem cells
US6828145B2 (en) 2000-05-10 2004-12-07 Cedars-Sinai Medical Center Method for the isolation of stem cells by immuno-labeling with HLA/MHC gene product marker
WO2001091548A2 (en) * 2000-06-01 2001-12-06 Pharmacia & Upjohn Company Mice heterozygous for wfs1 gene as mouse models for depression
EP1290444B1 (de) * 2000-06-14 2009-10-07 Vistagen, Inc. Toxizitätstypisierung unter verwendung von leberstammzellen
AU2001284703B2 (en) * 2000-08-03 2007-03-22 Therapeutic Human Polyclonals Inc. Production of humanized antibodies in transgenic animals
EP2138583A1 (de) 2000-12-22 2009-12-30 Institut National De La Recherche Agronomique Positionsunabhängige und gewebespezifische Expression eines Transgens in der Milch eines Transgen-Tieres
US20040121460A1 (en) * 2001-01-24 2004-06-24 Lumelsky Nadya L Differentiation of stem cells to pancreatic endocrine cells
US20030211605A1 (en) * 2001-05-01 2003-11-13 Lee Sang-Hun Derivation of midbrain dopaminergic neurons from embryonic stem cells
US7129034B2 (en) * 2001-10-25 2006-10-31 Cedars-Sinai Medical Center Differentiation of whole bone marrow
US6759244B2 (en) 2001-11-08 2004-07-06 Art Institute Of New York And New Jersey, Inc. Composite blastocysts (CBs) from aggregates of dissociated cells of non-viable pre-embryos
GB0220145D0 (en) * 2002-08-30 2002-10-09 Thromb X Nv Novel compositions for the in vitro derivation and culture of embryonic stem (ES) cell lines with germline transmission capability
US20030207448A1 (en) * 2002-05-06 2003-11-06 Revera Gregory Henry Methodologies for the creation of pluripotent or multipotent human stem cells without creating or destroying a human embryo
US8293488B2 (en) 2002-12-09 2012-10-23 Neuralstem, Inc. Method for screening neurogenic agents
US20040185429A1 (en) 2002-12-09 2004-09-23 Judith Kelleher-Andersson Method for discovering neurogenic agents
DK1572984T3 (en) * 2002-12-16 2016-06-13 Technion Res & Dev Foundation FEEDER CELL-FREE, XENOPHRIC CULTIVATION SYSTEM FOR HUMAN EMBRYONAL STEM CELLS
US20040191839A1 (en) * 2003-03-28 2004-09-30 National Institute Of Agrobiological Sciences Japan Methods for sorting undifferentiated cells and uses thereof
IL155783A (en) 2003-05-05 2010-11-30 Technion Res & Dev Foundation Multicellular systems of multi-potential embryonic human stem cells and cancer cells and their use
WO2006040615A2 (en) * 2003-06-11 2006-04-20 Jan Remmereit Differenciation of stem cells for therapeutic use
PL1758986T3 (pl) 2004-06-09 2016-03-31 Univ Court Univ Of Edinburgh Nerwowe komórki macierzyste
US20050277124A1 (en) 2004-06-10 2005-12-15 White Steven M Cardiac conduction system cells and uses thereof
CA2570086A1 (en) * 2004-06-10 2005-12-29 Merial Limited Medium and methods for culturing of avian primordial germ cells
EP1833300A4 (de) * 2004-08-16 2009-05-27 Univ Dayton Stammzellen ähnliche zellen
IN2014CN03629A (de) * 2004-11-17 2015-09-04 Neuralstem Inc
CN1298843C (zh) * 2005-02-07 2007-02-07 十堰市太和医院 不依赖饲养细胞的人胚干细胞培养基
EP1910516B1 (de) * 2005-06-22 2019-06-19 Asterias Biotherapeutics, Inc. Suspensionskultur menschlicher embryonaler stammzellen
MY154677A (en) 2006-03-07 2015-07-15 Shroff Geeta Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
EP2101724B1 (de) 2006-05-11 2020-12-02 Regenics AS Verabreichung von zellextrakten zur verjüngung
US20080003676A1 (en) * 2006-06-26 2008-01-03 Millipore Corporation Growth of embryonic stem cells
JP5087625B2 (ja) 2006-09-01 2012-12-05 セラピューティック・ヒューマン・ポリクローナルズ・インコーポレーテッド 非ヒトトランスジェニック動物におけるヒトまたはヒト化免疫グロブリンの発現強化
US8685720B2 (en) * 2006-11-03 2014-04-01 The Trustees Of Princeton University Engineered cellular pathways for programmed autoregulation of differentiation
US20080206864A1 (en) * 2006-11-22 2008-08-28 Derrick Rancourt Methods and Materials for Culturing Murine Embryonic Stem Cells
US20080267874A1 (en) * 2007-03-28 2008-10-30 The Buck Institute For Age Research Targeted Neuronal And Glial Human Embryonic Stem Cell Line
EP2296676B1 (de) 2008-05-09 2016-11-02 Regenics AS Zellextrakte
WO2010075500A1 (en) 2008-12-23 2010-07-01 Stemcells California, Inc Target populations of oligodendrocyte precursor cells and methods of making and using same
WO2010096496A2 (en) 2009-02-17 2010-08-26 Memorial Sloan-Kettering Cancer Center Methods of neural conversion of human embryonic stem cells
CN101962630B (zh) * 2009-07-23 2013-04-10 北京大学 诱导人胚胎干细胞或人诱导形成的多潜能干细胞向肝细胞分化的方法
AU2011249478B2 (en) 2010-05-06 2014-12-04 Regenics As Use of cellular extracts for skin rejuvenation
US9540611B2 (en) 2010-07-28 2017-01-10 Neuralstem, Inc. Methods for treating and/or reversing neurodegenerative diseases and/or disorders
ES2779453T3 (es) 2011-11-04 2020-08-17 Memorial Sloan Kettering Cancer Center Neuronas de dopamina (DA) del mesencéfalo para injerto
CA2894448C (en) 2012-12-10 2019-09-17 Regenics As Use of cellular extracts for skin rejuvenation
WO2014176606A1 (en) 2013-04-26 2014-10-30 Memorial Sloan-Kettering Center Center Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells
AU2014352773B2 (en) 2013-11-21 2021-04-29 Memorial Sloan-Kettering Cancer Center Specification of functional cranial placode derivatives from human pluripotent stem cells
US20180363070A9 (en) 2014-08-12 2018-12-20 Univ Wayne State Systems and methods to detect stem cell stress and uses thereof
CA2964927C (en) 2014-10-20 2019-07-30 Neuralstem, Inc. Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof
BR112018074192A8 (pt) 2016-05-25 2022-11-08 Inst Nat Sante Rech Med Método para tratamento de um sujeito, método para produzir uma composição celular, composição de células, composição de vacina e kit
KR20200111168A (ko) 2017-11-24 2020-09-28 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 암 치료를 위한 방법 및 조성물
EP3833383A1 (de) 2018-08-06 2021-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und zusammensetzungen zur behandlung von krebs
WO2022207889A1 (en) 2021-04-01 2022-10-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Liver organoid manufacturing methods, liver organoids obtained with the same, and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT87133B (pt) * 1987-04-02 1992-07-31 Amrad Corp Ltd Metodo de purificacao do factor inibidor da leucemia (lif) e de composicoes farmaceuticas contendo polipeptidos com actividade do lif

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Volume 105, issued 18 August 1987, (Columbus, Ohio, U.S.A.) R.H. LOVELL - BADGE et al. "Transformation of Embryonic Stem Cells with the Human Type-III Collagen Gene and its Expression in Chimeric Mice", see page 169, column 2, Abstract No. 556346, Cold Spring Harbour Symp. Quant. Biol. 1985, 50(Mol. Biol. Dev.), 707-11. *
CHEMICAL ABSTRACTS, Volume 108, issued 14 March 1988, (Columbus, Ohio, U.S.A.) D.P. GEARING et al. "Molecular Cloning and Expression of cDNA Encoding a Murine Myeloid Leukemia Inhibitory Factor (LIF)", see page 159, column 1, Abstract No. 88918n, EMBO J. 1987, 6 (13), 3995-4002. *
CHEMICAL ABSTRACTS, Volume 109, issued 15 August 1988, (Columbus, Ohio, U.S.A.), D.J. HILTON et al. "Resolution and Purification of three Distinct Factors Produced by Krebs Ascines Cells which have Differentiation - Inducing Activity on Murine Myeloid Leukemia Cell Lines", see page 522, column 2, Abstract No. 529518, J. Biol. Chem. 1988, 263 (19), 9238-43. *
HEATH, J.K. and A.G. SMITH, "Regulatory Factors of Embryonic Stem Cells", Journal of Cell Science, Supplement, Volume 10, issued 1988, (The Company of Biologists Limited 1988, Great Britain), see pages 257 to 266. *
SMITH, A.G. and M.L. HOOPER, "Buffalo Rat Liver Cells Produce a Diffusable Activity which Inhibits the Differentiation of Murine Embryonal Carcinoma and Embryonic Stem Cell", Developmental Biology, Volume 121, issued 1987 (Academic Press, Inc. USA), see pages 1 to 9. *
SMITH, A.G. et al. "Inhibition of Pluripotential Embryonic Stem Cell Differentiation by Purified Polypeptides", Nature, Volume 336 issued 15 December 1988, (USA), see pages 688 to 690. *
WILLIAMS, R.L. et al. "Myeloid Leukaemia Inhibitory Factor Maintains the Developmental Potential of Embryonic Stem Cells", Nature, Volume 336, issued 15 December 1988, (USA), see pages 684 to 687. *

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0651787A1 (de) * 1990-07-09 1995-05-10 Amrad Corporation Limited Verbesserte implantation, entwicklung und versorgung von embryonen bei verwendung von leukämieinhibtions-faktor
US5712156A (en) * 1990-07-09 1998-01-27 Amrad Corporation Limited Enhanced implantation, development and maintenance of embryos using leukaemia inhibitory factor
US5366888A (en) * 1990-07-09 1994-11-22 Amrad Corporation Limited Enhanced maintenance of pregnancy using leukaemia inhibitory factor in embryo culturing
EP0651787A4 (de) * 1990-07-09 1993-07-27 Amrad Corp Ltd Verbesserte implantation, entwicklung und versorgung von embryonen bei verwendung von leukämieinhibtions-faktor.
US5698763A (en) * 1991-11-14 1997-12-16 Weissmann; Charles Transgenic animals lacking prion proteins
US7459600B2 (en) 1993-04-21 2008-12-02 The University Of Edinburgh Isolation, selection and propagation of animal transgenic stem cells
US7256041B2 (en) 1993-04-21 2007-08-14 The University Of Edinburgh Isolation, selection and propagation of animal transgenic stem cells
US6878542B1 (en) 1993-04-21 2005-04-12 The University Of Edinburgh Isolation, selection and propagation of animal transgenic stem cells
US6146888A (en) * 1993-04-21 2000-11-14 The University Of Edinburgh Method of enriching for mammalian stem cells
WO1994024274A1 (en) * 1993-04-21 1994-10-27 The University Of Edinburgh Isolation, selection and propagation of animal transgenic stem cells
US5942435A (en) * 1993-05-14 1999-08-24 The Board Of Trustees Of The University Of Illinois Transgenic swine compositions and methods
US7071373B1 (en) 1993-05-14 2006-07-04 The Board Of Trustees Of The University Of Illinois Transgenic ungulate compositions and methods
WO1994026884A1 (en) * 1993-05-14 1994-11-24 Biotechnology Research And Development Corporation Embryonic stem cells for making chimeric and transgenic ungulates
WO1995006716A1 (en) * 1993-08-30 1995-03-09 Northwestern University Rat pluripotent embryonic stem cells and method of obtaining and using same
EP0725817A1 (de) * 1993-11-03 1996-08-14 Diacrin, Inc. Stammzellen aus embryonen, die in der lage sind, zu gewünschten zelllinien auszudifferenzieren
EP0725817A4 (de) * 1993-11-03 1999-12-22 Diacrin Inc Stammzellen aus embryonen, die in der lage sind, zu gewünschten zelllinien auszudifferenzieren
WO1995020042A1 (en) * 1994-01-25 1995-07-27 Ppl Therapeutics (Scotland) Limited Embryonic stem cell isolation
US6998266B2 (en) 1994-10-21 2006-02-14 Institute National De La Recherche Agronomique Active retinoic acid-free culture medium for avian totipotent embryonic stem cells
EP1149899A1 (de) * 1994-10-21 2001-10-31 Institut National De La Recherche Agronomique Kulturmedium von Vögeln totipotenten embryonalen Zellen
WO1996012793A1 (fr) * 1994-10-21 1996-05-02 Institut National De La Recherche Agronomique Milieu de culture de cellules embryonnaires totipotentes aviaires, depourvu d'acide retinoique actif
US6500668B2 (en) 1994-10-21 2002-12-31 Jacques Samarut Culture medium for avian embryonic cells
US6114168A (en) * 1994-10-21 2000-09-05 Institute National De La Recherche Agronomique Active retinoic acid-free culture medium for chicken embryonic stem cells
FR2726003A1 (fr) * 1994-10-21 1996-04-26 Agronomique Inst Nat Rech Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires
WO1997041209A1 (en) * 1996-04-29 1997-11-06 Leuven Research & Development Vzw Pluripotent rabbit embryonic stem (es) cell lines and their use in the generation of chimeric rabbits
WO1997047734A1 (en) * 1996-06-14 1997-12-18 The Regents Of The University Of California In vitro derivation and culture of primate pluripotent stem cells and therapeutic uses thereof
US6395958B1 (en) 1997-03-06 2002-05-28 Infigen, Inc. Method of producing a polypeptide in an ungulate
WO1998039416A1 (en) * 1997-03-06 1998-09-11 Infigen, Inc. Method of cloning animals
US6603059B1 (en) 1997-03-06 2003-08-05 Infigen, Inc. Method of cloning animals
WO2003054169A1 (en) * 2001-12-21 2003-07-03 Thromb-X Nv Compositions for the in vitro derivation and culture of embryonic stem (es) cell lines with germline transmission capability
US8697444B2 (en) 2001-12-21 2014-04-15 Thrombogenics N.V. Compositions for the in vitro derivation and culture of embryonic stem (ES) cell lines with germline transmission capability and for the culture of adult stem cells
US8993323B2 (en) 2001-12-21 2015-03-31 Thrombogenics N.V. Compositions for the in vitro derivation and culture of embryonic stem (ES) cell lines with germline transmission capability and for the culture of adult stem cells
WO2003054170A1 (en) * 2001-12-21 2003-07-03 Thromb-X Nv Compositions for the in vitro derivation and culture of embryonic stem (es) cell lines with germline transmission capability and for the culture of adult stem cells
US7145057B2 (en) 2002-02-01 2006-12-05 Origen Therapeutics, Inc. Chimeric bird from embryonic stem cells
US9382513B2 (en) 2002-03-08 2016-07-05 Valneva Method of making an avian cell line
WO2004039965A1 (ja) * 2002-10-31 2004-05-13 Riken 多能性幹細胞培養用の組成物とその使用
US7700352B2 (en) 2002-10-31 2010-04-20 Riken Composition for culturing mouse pluripotent stem cells
US8962311B2 (en) 2006-08-09 2015-02-24 Valneva Method of obtaining chicken embryonic stem cells
US9822345B2 (en) 2007-04-24 2017-11-21 Valneva Method of making a virus using duck embryonic derived stem cell lines
US9260694B2 (en) 2007-04-24 2016-02-16 Valneva Generation of duck cell lines

Also Published As

Publication number Publication date
NO322243B1 (no) 2006-09-04
DE68928914D1 (de) 1999-03-04
EP0380646B1 (de) 1999-01-20
US5166065A (en) 1992-11-24
EP0380646A4 (en) 1991-01-23
AU623922B2 (en) 1992-05-28
DE68928914T2 (de) 1999-09-09
JP2740320B2 (ja) 1998-04-15
DK17091A (da) 1991-04-04
EP0380646A1 (de) 1990-08-08
AU4059089A (en) 1990-03-05
DK176238B1 (da) 2007-04-10
HK1003208A1 (en) 1998-10-16
NO910385L (no) 1991-04-04
JPH03503241A (ja) 1991-07-25
CA1341469C (en) 2004-12-28
DK17091D0 (da) 1991-01-31
ATE175994T1 (de) 1999-02-15
NO910385D0 (no) 1991-02-01

Similar Documents

Publication Publication Date Title
US5166065A (en) In vitro propagation of embryonic stem cells
US7186883B2 (en) In vitro propagation of embryonic stem cells
US7459600B2 (en) Isolation, selection and propagation of animal transgenic stem cells
Pease et al. Isolation of embryonic stem (ES) cells in media supplemented with recombinant leukemia inhibitory factor (LIF)
US5942435A (en) Transgenic swine compositions and methods
Sofikitis et al. Efforts to create an artificial testis: culture systems of male germ cells under biochemical conditions resembling the seminiferous tubular biochemical environment
US6156569A (en) Prolonged culturing of avian primordial germ cells (PGCs) using specific growth factors, use thereof to produce chimeric avians
US8993323B2 (en) Compositions for the in vitro derivation and culture of embryonic stem (ES) cell lines with germline transmission capability and for the culture of adult stem cells
US20140127812A1 (en) Long-term culture of avian primordial germ cells (pgcs)
EP1007633A1 (de) Primordiale keimzellinie aus vögeln und verfahren zu deren langzeitkultivierung
JP4374419B2 (ja) 多能性幹細胞培養用の組成物とその使用
WO1994007997A1 (en) Long-term proliferation of primordial germ cells
McLaren Germ cells and germ cell transplantation
US20040096971A1 (en) Thymic epithelial progenitor cells and uses thereof
US20050059145A1 (en) Compositions for the in vitro derivation and culture of embryonic stem (es) cell lines with germline transmission capability and for the culture of adult stem cells
WO2000008132A1 (en) Prolonged culturing of avian primordial germ cells using specific growth factors and use thereof
Biery Ultrastructural characterization of tential embryonic stem cells in murine and bovine embryos
MXPA00001301A (en) Avian primordial germ cell (pgc) cell line and a method for long term culturing thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU DK JP NO US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

CR1 Correction of entry in section i
WWE Wipo information: entry into national phase

Ref document number: 1989909126

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1989909126

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1989909126

Country of ref document: EP